KR20080016647A - 프라수그렐에 대한 투여 계획 - Google Patents
프라수그렐에 대한 투여 계획 Download PDFInfo
- Publication number
- KR20080016647A KR20080016647A KR1020077029366A KR20077029366A KR20080016647A KR 20080016647 A KR20080016647 A KR 20080016647A KR 1020077029366 A KR1020077029366 A KR 1020077029366A KR 20077029366 A KR20077029366 A KR 20077029366A KR 20080016647 A KR20080016647 A KR 20080016647A
- Authority
- KR
- South Korea
- Prior art keywords
- prasugrel
- formula
- compound
- equivalent
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960004197 prasugrel Drugs 0.000 title claims abstract description 97
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 239000005465 B01AC22 - Prasugrel Substances 0.000 title claims abstract description 80
- 238000012423 maintenance Methods 0.000 claims abstract description 43
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 208000019553 vascular disease Diseases 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 35
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 22
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 22
- 208000007536 Thrombosis Diseases 0.000 claims description 17
- 208000005189 Embolism Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 208000001435 Thromboembolism Diseases 0.000 claims description 10
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 9
- JALHGCPDPSNJNY-UHFFFAOYSA-N [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4h-thieno[3,2-c]pyridin-2-yl] acetate;hydron;chloride Chemical compound Cl.C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 JALHGCPDPSNJNY-UHFFFAOYSA-N 0.000 claims description 9
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 9
- 229960004947 prasugrel hydrochloride Drugs 0.000 claims description 7
- 150000003840 hydrochlorides Chemical class 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 5
- -1 α-cyclopropylcarbonyl-2-fluorobenzyl Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 26
- 229960003009 clopidogrel Drugs 0.000 description 26
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 26
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 13
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 13
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 206010019280 Heart failures Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 6
- 229940125670 thienopyridine Drugs 0.000 description 6
- 239000002175 thienopyridine Substances 0.000 description 6
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940127218 antiplatelet drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 229940047170 clopidogrel 300 mg Drugs 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000007214 atherothrombosis Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229940066015 clopidogrel 75 mg Drugs 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000013152 interventional procedure Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- WJFYLCXWEXZNHU-UHFFFAOYSA-N 2,3,3a,4-tetrahydrothieno[3,2-b]pyridine Chemical class N1C=CC=C2SCCC21 WJFYLCXWEXZNHU-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000035211 Heart Murmurs Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100001347 Mus musculus Akt1s1 gene Proteins 0.000 description 1
- IJXHLRLPCYQJAB-UHFFFAOYSA-N O=C(CC(C=CC=C1)=C1F)C1CC1.Cl Chemical compound O=C(CC(C=CC=C1)=C1F)C1CC1.Cl IJXHLRLPCYQJAB-UHFFFAOYSA-N 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003684 cardiac depression Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229940101750 prasugrel 10 mg Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- AEMXNRIHRLEYAK-UHFFFAOYSA-N pyridin-2-yl acetate Chemical compound CC(=O)OC1=CC=CC=N1 AEMXNRIHRLEYAK-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69174005P | 2005-06-17 | 2005-06-17 | |
| US60/691,740 | 2005-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080016647A true KR20080016647A (ko) | 2008-02-21 |
Family
ID=37571073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077029366A Ceased KR20080016647A (ko) | 2005-06-17 | 2006-06-13 | 프라수그렐에 대한 투여 계획 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090156632A1 (https=) |
| EP (1) | EP1893205A4 (https=) |
| JP (1) | JP2008543853A (https=) |
| KR (1) | KR20080016647A (https=) |
| CN (1) | CN101198329A (https=) |
| AU (1) | AU2006259538A1 (https=) |
| BR (1) | BRPI0612624A2 (https=) |
| CA (1) | CA2612315A1 (https=) |
| EA (1) | EA200800075A1 (https=) |
| EC (1) | ECSP078014A (https=) |
| GT (1) | GT200600263A (https=) |
| IL (1) | IL187486A0 (https=) |
| MA (1) | MA29722B1 (https=) |
| MX (1) | MX2007015430A (https=) |
| NO (1) | NO20080244L (https=) |
| TN (1) | TNSN07474A1 (https=) |
| WO (1) | WO2006138317A2 (https=) |
| ZA (1) | ZA200710769B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5274261B2 (ja) | 2006-12-07 | 2013-08-28 | 第一三共株式会社 | 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物 |
| EP2100607A4 (en) * | 2006-12-07 | 2010-01-06 | Daiichi Sankyo Co Ltd | COATING COMPOSITION WITH IMPROVED DURABILITY |
| CN101686681B (zh) | 2007-04-27 | 2015-04-01 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| WO2010132711A1 (en) | 2009-05-13 | 2010-11-18 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| US10376532B2 (en) * | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| EP2409685A3 (en) | 2010-07-19 | 2012-02-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-disintegrating formulations of prasugrel |
| TR201006802A1 (tr) * | 2010-08-17 | 2012-03-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Prasugrelin oral yolla dağılan formülasyonları. |
| EP3106151A1 (en) | 2015-06-19 | 2016-12-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical compositions of prasugrel hydrobromide |
| WO2018167447A1 (en) * | 2017-03-14 | 2018-09-20 | University Of Sheffield | Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| US6544981B2 (en) * | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
| JP4001199B2 (ja) * | 2000-07-06 | 2007-10-31 | 第一三共株式会社 | ヒドロピリジン誘導体酸付加塩 |
| ATE398624T1 (de) * | 2000-07-06 | 2008-07-15 | Daiichi Sankyo Co Ltd | Säure-additionssalze von hydropyridinderivaten |
| JP4874482B2 (ja) * | 2000-12-25 | 2012-02-15 | 第一三共株式会社 | アスピリンを含有する医薬組成物 |
| NZ526540A (en) * | 2000-12-25 | 2004-11-26 | Sankyo Co | Medicinal compositions containing aspirin and 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-flurobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine useful in preventing thrombus or embolus diseases |
| JP2006525328A (ja) * | 2003-05-05 | 2006-11-09 | イーライ リリー アンド カンパニー | 心疾患の治療方法 |
-
2006
- 2006-06-13 BR BRPI0612624A patent/BRPI0612624A2/pt not_active IP Right Cessation
- 2006-06-13 EP EP06773053A patent/EP1893205A4/en not_active Withdrawn
- 2006-06-13 KR KR1020077029366A patent/KR20080016647A/ko not_active Ceased
- 2006-06-13 JP JP2008517022A patent/JP2008543853A/ja active Pending
- 2006-06-13 CN CNA2006800217943A patent/CN101198329A/zh active Pending
- 2006-06-13 AU AU2006259538A patent/AU2006259538A1/en not_active Abandoned
- 2006-06-13 MX MX2007015430A patent/MX2007015430A/es unknown
- 2006-06-13 EA EA200800075A patent/EA200800075A1/ru unknown
- 2006-06-13 WO PCT/US2006/023006 patent/WO2006138317A2/en not_active Ceased
- 2006-06-13 US US11/916,817 patent/US20090156632A1/en not_active Abandoned
- 2006-06-13 CA CA002612315A patent/CA2612315A1/en not_active Abandoned
- 2006-06-16 GT GT200600263A patent/GT200600263A/es unknown
-
2007
- 2007-11-19 IL IL187486A patent/IL187486A0/en unknown
- 2007-12-11 ZA ZA200710769A patent/ZA200710769B/xx unknown
- 2007-12-14 TN TNP2007000474A patent/TNSN07474A1/en unknown
- 2007-12-14 EC EC2007008014A patent/ECSP078014A/es unknown
-
2008
- 2008-01-14 NO NO20080244A patent/NO20080244L/no not_active Application Discontinuation
- 2008-01-16 MA MA30577A patent/MA29722B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006259538A1 (en) | 2006-12-28 |
| IL187486A0 (en) | 2008-06-05 |
| US20090156632A1 (en) | 2009-06-18 |
| CA2612315A1 (en) | 2006-12-28 |
| ZA200710769B (en) | 2009-09-30 |
| EP1893205A2 (en) | 2008-03-05 |
| CN101198329A (zh) | 2008-06-11 |
| MA29722B1 (fr) | 2008-09-01 |
| TNSN07474A1 (en) | 2009-03-17 |
| ECSP078014A (es) | 2008-01-23 |
| MX2007015430A (es) | 2008-02-21 |
| WO2006138317A2 (en) | 2006-12-28 |
| GT200600263A (es) | 2007-02-23 |
| EP1893205A4 (en) | 2010-06-30 |
| NO20080244L (no) | 2008-01-14 |
| WO2006138317A3 (en) | 2007-05-03 |
| JP2008543853A (ja) | 2008-12-04 |
| BRPI0612624A2 (pt) | 2016-11-29 |
| EA200800075A1 (ru) | 2008-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100692934B1 (ko) | 아스피린을 함유하는 의약 조성물 | |
| US20080176893A1 (en) | Formulation of a Thienopyridine Platelet Aggregation Inhibitor | |
| US20080214599A1 (en) | Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases | |
| KR20240060820A (ko) | 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안 | |
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| HUP0203585A2 (hu) | Gyógyszerkombinációk | |
| KR20080016647A (ko) | 프라수그렐에 대한 투여 계획 | |
| JP2024541514A (ja) | 進行性線維化を伴う間質性肺疾患を処置するための、新たな治療的組合せ | |
| US20250025466A1 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| JP2025525915A (ja) | 虚血性脳卒中を処置又は予防するためのミルベクシアンの使用 | |
| CN100577170C (zh) | 吡唑并嘧啶类Src家族酪氨酸激酶抑制剂在制备治疗心肌梗死的药物中的应用 | |
| WO2005070427A1 (en) | Compounds for the sustained reduction of body weight | |
| Turpie | Warfarin replacements: mechanisms underlying emerging agents | |
| Klockowski et al. | Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers | |
| HK40115216A (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| EP4271375A1 (en) | Methods of treatment | |
| KR20260051984A (ko) | 급성 관상동맥 증후군을 갖는 환자에서 유해 뇌혈관 사건 또는 유해 심혈관 사건을 치료 또는 예방하기 위한 밀벡시안의 용도 | |
| TW202448437A (zh) | 米爾維仙(milvexian)於治療及預防患有心房震顫之患者之血栓病況的用途 | |
| WO2011052499A1 (ja) | 貯蔵安定性が改善された医薬組成物 | |
| EP2387996A1 (en) | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation | |
| Vet—QC09CA02 | Eprosartan Mesilate (BANM, rINNM) | |
| HK1158984A (en) | Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack | |
| TW201200131A (en) | Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with premanent atrial fibrillation | |
| HK1116422B (en) | Formulation of a thienopyridine platelet aggregation inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20071214 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20071214 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20091020 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20091229 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20091020 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |